PetMeds trims Q4 loss as sales decline continues
Bottom line
PetMeds said its fiscal fourth-quarter revenue fell 15.6% year over year to $42.8 million for the quarter ended March 31, 2026, extending the company’s broader sales slide, but its net loss narrowed to $4.1 million from $11.6 million a year earlier. The company said lower general and administrative expenses, the absence of a prior-year trade name impairment charge, and higher interest income helped offset weaker sales, which were still pressured mainly by declining prescription medication revenue. Management also pointed to a modest sequential sales increase from Q3, improved gross margin, and a new white-label pharmacy partnership with Rural King as part of its effort to stabilize the business and expand beyond direct-to-consumer sales. (globenewswire.com)
Why it matters: For veterinary professionals, PetMeds’ results are another sign that the online pet pharmacy market remains under pressure, even as major players look for new ways to grow. The company is leaning into B2B pharmacy fulfillment, membership programs, and rural retail partnerships, which could widen medication access for pet parents, especially in underserved communities, while also increasing competition around prescription fulfillment and client retention. PetMeds also said it remediated previously disclosed material weaknesses in internal controls after a whistleblower-related investigation, an important credibility issue for clinics, partners, and vendors watching the company’s stability. (fool.com)
What to watch: Watch whether PetMeds can turn its Rural King partnership and other B2B efforts into measurable revenue growth over the next few quarters, because the company hasn’t yet disclosed financial terms or a rollout timeline. (stocktitan.net)
PetMeds narrowed its fiscal fourth-quarter loss, but the bigger story is that revenue is still falling. In results released June 2, 2026, the company reported Q4 net sales of $42.8 million, down 15.6% from $50.8 million a year earlier, while net loss improved to $4.1 million from $11.6 million. Management framed the quarter as an early sign of stabilization, citing a sequential sales increase from the prior quarter, but the company is still working to reverse a prolonged decline in prescription medication sales. (globenewswire.com)
That pressure has been building for some time. For the full fiscal year ended March 31, 2026, PetMeds posted net sales of $179.0 million, down 21.1% from $227.0 million the year before, and a net loss of $57.3 million, compared with a $6.3 million loss in fiscal 2025. The full-year result was weighed down by a $26.7 million goodwill impairment, a $2.1 million wholesale inventory write-down tied to what management called an unsuccessful non-core initiative, and $4.5 million in legal, professional, and severance costs related to a previously disclosed whistleblower investigation. (globenewswire.com)
The company’s recent history helps explain why investors and industry partners are watching closely. In 2025, PetMeds delayed filings and disclosed an internal investigation tied to whistleblower complaints involving revenue recognition on certain AutoShip orders, a coupon promotion, and concerns about company culture and controls. On the latest earnings call, management said it had regained regulatory compliance in late 2025 and fully remediated three previously disclosed material weaknesses related to tone at the top, complex accounting issues, and income taxes. (stocktitan.net)
In the quarter itself, PetMeds said lower operating expenses and improved gross margin helped narrow the loss, even though adjusted EBITDA worsened to a loss of $2.8 million from a $1.9 million loss a year earlier. Management said the quarter included a 270-basis-point gross margin improvement to 32.6%, and described “green shoots” in the second half of the year, including better trends in prescription medication sales, food, and auto-ship signups. The company also said cost actions taken in the back half of fiscal 2026, including exiting underperforming vendor relationships, should deliver about $6.1 million in annualized savings. (globenewswire.com)
PetMeds is also trying to change the shape of its business. In April 2026, it announced a strategic partnership with Rural King to launch a white-label pet pharmacy across the retailer’s stores and digital channels. PetMeds said it will provide pharmacy infrastructure, licensed pharmacists, and e-commerce capabilities, marking its first large-scale white-label pharmacy program and a push into B2B fulfillment. Management highlighted that agreement again in the Q4 release and earnings call as a key part of its growth strategy. However, the company hasn’t disclosed financial terms or a public rollout timeline, so it’s still too early to judge the revenue impact. (stocktitan.net)
Industry-wise, the strategy is notable because it suggests PetMeds sees more opportunity in being a pharmacy platform than in relying only on its legacy direct-to-consumer model. That could matter for veterinary practices in rural and mixed-animal markets, where Rural King already has a strong footprint and where access to medications can be more fragmented. If the partnership scales, clinics may see another retail-adjacent prescription channel competing for routine fills, preventives, and chronic medication refills, while pet parents may gain more convenient access points. That’s an inference based on PetMeds’ stated strategy and Rural King’s national store base in 17 states. (stocktitan.net)
Why it matters: For veterinary professionals, this isn’t just a retail earnings story. PetMeds’ continued revenue decline shows the online pharmacy channel is still under strain, but its pivot toward white-label fulfillment and partnership models could reshape how prescriptions move outside the clinic. The company remains licensed across all 50 states and is positioning itself as infrastructure for other brands, not just a consumer-facing pharmacy. If that model gains traction, practices may need to pay even closer attention to refill leakage, pricing transparency, client communication, and how to preserve continuity of care when pet parents have more retail pharmacy options. (stocktitan.net)
What to watch: The next key markers are whether PetMeds can convert its second-half “green shoots” into sustained year-over-year improvement, whether the Rural King partnership begins contributing visible sales, and whether management can show cleaner execution after a year shaped by impairments, compliance work, and investigation-related costs. The company also disclosed that it received two unsolicited acquisition proposals in December 2025, but chose to remain independent, so strategic alternatives may remain part of the background if the turnaround stalls. (globenewswire.com)